This study allowed the distribution assessment of the main clinical and pathological characteristics and those related to health services in a cohort of Brazilian women with breast cancer, according to the immunohistochemical tumor subtypes.
BackgroundMitral valve regurgitation (MR), present in up to 74% of the patients with
severe aortic stenosis (AS), can be a negative prognostic factor when
moderate or severe. The outcome of MR after percutaneous transcatheter
aortic valve implantation (TAVI) and predictors associated with that outcome
have not been well established in the literature.ObjectiveTo assess the outcome of primary MR in patients submitted to TAVI and to
identify associated factors.MethodsObservational study of patients with symptomatic severe AS submitted to TAVI
from January 2009 to April 2015 at two specialized centers.
Echocardiographic outcome was assessed with data collected before and 1 year
after TAVI.ResultsOf the 91 patients with MR submitted to TAVI and followed up for at least 12
months, 67 (73.6%) had minimum/mild MR before the procedure and 24 (26.4%)
had moderate/severe MR. Of those with minimum/mild MR, 62 (92.5%) had no
change in the MR grade (p < 0.001), while 5 (7.5%) showed worsening. Of
those with moderate/severe MR, 8 (33.3%) maintained the same grade and 16
(66.7%) improved it (p = 0.076). Patients with moderate/severe MR who
improved MR grade had lower EuroSCORE II (p = 0.023) and STS morbidity (p =
0.027) scores, as compared to those who maintained the MR grade.ConclusionMR grades change after TAVI. This study suggests a trend towards improvement
in moderate/severe MR after TAVI, which was associated with lower
preoperative risk scores.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.